Efficacy and Safety of Tetrabenazine in Chorea
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00219804 |
Recruitment Status :
Completed
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Huntington's Disease | Drug: tetrabenazine or placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or older
- suffer from manifest HD as confirmed by genetic testing
- Meet chorea and total functional capacity scores on Unified Huntington's Disease Rating Scale
- Meet criteria on Hamilton Depression Rating Scale, Unified Parkinson's Disease Rating Scale dysphagia and dysarthria scale
- Independently ambulatory
Exclusion Criteria
- previous treatment with tetrabenazine
- unstable or serious medical or psychiatric illness
- concomitant use identified drugs
- untreated depression
- lack of caregiver

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00219804
Principal Investigator: | Fred Marshall, M.D. | Huntington's Study Group |
ClinicalTrials.gov Identifier: | NCT00219804 |
Other Study ID Numbers: |
103,004 |
First Posted: | September 22, 2005 Key Record Dates |
Last Update Posted: | September 22, 2005 |
Last Verified: | September 2005 |
Huntington Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Dementia Chorea Dyskinesias Movement Disorders Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn |
Cognition Disorders Neurocognitive Disorders Mental Disorders Tetrabenazine Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Adrenergic Agents Neurotransmitter Agents Physiological Effects of Drugs |